Please login to the form below

Not currently logged in
Email:
Password:

Depomed and Watson sign co-promotion deal

Depomed and Watson Pharmaceuticals have entered into a co-promotion agreement for ProQuin XR, Depomed's extended-release formulation of ciprofloxacin for the treatment of uncomplicated urinary tract infections.

Depomed and Watson Pharmaceuticals have entered into a co-promotion agreement for ProQuin XR, Depomed's extended-release formulation of ciprofloxacin for the treatment of uncomplicated urinary tract infections.

Under the agreement, Depomed has granted Watson a co-exclusive right to promote ProQuin XR for the urology and long-term care specialties in the US and its possessions, including Puerto Rico.

Per the agreement, Depomed will book top-line revenue and Watson will receive a portion of the profits. Watson and Depomed plan to re-launch ProQuin XR in the US urology market by the end of this year.

Depomed retains manufacturing and distribution rights and Watson will be responsible for promotion to physicians in urology and long-term care.

Extended release versions of ciprofloxacin are also sold by Germany-based Bayer and Indian pharmaceutical company Ranbaxy.

According to a Market Research report, fluoroquinolone sales are expected to remain relatively constant to 2011. The fluoroquinolone market is heavily dominated by ciprofloxacin and levofloxacin, which together command 65 per cent (USD 3.3bn) of global sales.

25th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics